 |
answer text |
<p>Our priority is to ensure that patients in all parts of the United Kingdom continue
to have access to medicines and medical products they need, including inhalers. We
continue to work closely with industry, the National Health Service and others in
the supply chain to deliver the shared goal of continuity of safe patient care by
mitigating any potential disruption to supply into the UK of medicines and medical
products at the end of the transition period, in all scenarios.</p><p>As set out in
a letter from the Department to industry of 3 August, we are implementing a multi-layered
approach, that involves asking suppliers of medicines and medical products to the
UK from or via the European Union to get trader ready, reroute their supply chains
away from any potential disruption and stockpiling to a target level of six weeks
on UK soil where this is possible. The letter is available at the following link:</p><p><a
href="https://www.gov.uk/government/publications/letter-to-medicines-and-medical-products-suppliers-3-august-2020/letter-to-medicine-suppliers-3-august-2020"
target="_blank">https://www.gov.uk/government/publications/letter-to-medicines-and-medical-products-suppliers-3-august-2020/letter-to-medicine-suppliers-3-august-2020</a></p>
|
|
